2-Deoxy-d-glucose is a glucose molecule which has the 2-hydroxyl group replaced by hydrogen, so that it cannot undergo further glycolysis. As such; it acts to competitively inhibit the production of glucose-6-phosphate from glucose at the phosphoglucoisomerase level (step 2 of glycolysis).

The ability of 2-deoxy-d-glucose (2-DG) to interfere with d-glucose metabolism demonstrates that nutrient and energy deprivation is an efficient tool to suppress cancer cell growth and survival. Acting as a d-glucose mimic, 2-DG inhibits glycolysis ...

By using positron emission tomography (PET), radiolabelled 2-deoxyglucose can determine glucose metabolism, which is altered in diseases such as cardiovascular disease, tumors, and Alzheimer's disease. Therapeutically, 2-deoxyglucose is an investigational drug that is being studied as an anticancer and antiviral agent.

2-Deoxy-D-Glucose (2-Deoxyglucose) is a glucose analog that inhibits glycolysis via its actions on hexokinase, the rate limiting step of glycolysis. It is phosphorylated by hexokinase to 2-DG-P which can not be further metabolized by phosphoglucose isomerase.

2-Deoxy-D-glucose (2-DG, 2-deoxy-D-arabino-hexopyranose) is a natural , nonmetabolizable glucose analog and a competitive inhibitor of glycolysis in which the 2-hydroxyl group is replaced by hydrogen . 2-DG blocks the activity of different enzymes involved in glycolysis, leading to …

2-Deoxy-d-glucose, a glucose analogue differing from normal glucose only by removal of a single hydroxyl group at the 2 position, is a glycolytic inhibitor with novel anticonvulsant and disease-modifying antiepileptic properties. 2-Deoxy-d-glucose is preferentially delivered to brain regions in response to energy demand by an exquisitely ...

The exact mechanisms of action of 2-deoxyglucose is still being investigated, but it is known that in hypoxic cancer cells, 2-deoxyglucose is a glycolysis inhibitor that prevents ATP production and, ultimately, cell survival.

2-Deoxyglucose (2-DG) Aerobic respiration to generate ATP is a key bioenergetic mechanism for tumor and normal cells that relies on two distinct processes, glycolysis or OXPHOS [90]. ONC201 inhibited OXPHOS and combined synergistically with glycolysis inhibitor 2-DG to elicit anti-cancer effects in GBM.